Picture loading failed.

Pre-Made Motavizumab biosimilar, Whole Mab: Anti-RSV gpF therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Motavizumab (proposed INN, trade name Numax) is a humanized monoclonal antibody. It is being investigated by MedImmune (today a subsidiary of AstraZeneca) for the prevention of respiratory syncytial virus infection in high-risk infants. As of September 2009, it is undergoing Phase II and III clinical trials.

Order information


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-357-1mg 1mg 3090
GMP-Bios-ab-357-10mg 10mg 21890
GMP-Bios-ab-357-100mg 100mg 148000
GMP-Bios-ab-357-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Motavizumab biosimilar, Whole Mab: Anti-RSV gpF therapeutic antibody
INN Name Motavizumab
TargetRSV gpF
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusDiscontinued
100% SI Structure3qwo:AB:HL/3ixt:HL:AB/4zyp:NO:JL:KM/6oe5:BC
99% SI Structure5k8a:BA:FE:VM:HL/4jlr:AB:HL
95-98% SI StructureNone
Year Proposed2006
Year Recommended2007
CompaniesMedImmune
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedRespiratory syncytial virus infections
Development TechAffinity Matured from Palivizumab